STRAMA A 10 year perspective Swedish Strategic programme for the Rational use of Antimicrobial Agents and Surveillance of Resistance www.strama.se.

Slides:



Advertisements
Similar presentations
Regions for Economic Change: Networking for Results LMP Workshop 3C: When exchanging is good for innovation: Experiences from the Lisbon Monitoring Platform.
Advertisements

Family Doctor for All Overview & Research Opportunities Kristin Anderson Director, Primary Health Care Branch Applied Health Research.
Hotet från omvärlden ökar. Increased knowledge on an increasing problem number of hits in Pub-MED for (antibiotic or antimicrobial) + resistance by 5.
The Smart Specialisation Platform
5 th Annual Forum Wednesday 28 th April 2010 Royal Hospital Kilmainham ‘Promoting Positive Mental Health and Reducing Stigma’
STRENGTHENING REFERRAL SYSTEM TO IMPROVE MATERNAL HEALTH
1 EFPC congress Gőteborg 2012 Interprofessional Education for Primary Care Professionals L. van Amsterdam.
EU RTD + FP Cancer Treatment: A priority for patients in Europe 7 th European Health Forum Bad Gastein 7 October, 2004 Cornelius Schmaltz MD European.
G aps, challenges and opportunities Theo Verheij University Medical Center Utrecht Lower Respiratory Tract Infections in Primary Care.
Zaza Tsereteli, MD,MPH International Technical Adviser for HIV/AIDS/STD for TF/CBSS Task Force on Communicable Disease Control and Northern Dimension.
Antimicrobial resistance “One health fits all”
Driving the HCAI agenda, Widening the net Gaynor Evans.
Dorota Kilańska RN, PhD European Nursing Research Foundation (ENRF)
Ministry of Health and Social Affairs Families and children at risk of poverty and social exclusion.
Socialdepartementet Primary care and the care for the elderly.
Rare Diseases Working Group Luzern, 24 September 2010.
J. Karadzinska-Bislimovska, S.Risteska-Kuc Institute of Occupational Health -WHO Collaborating Center for Occupational Health,Skopje National health policy.
Essential Service # 7:. Why learn about the 10 Essential Services?  Improve quality and performance.  Achieve better outcomes – improved health, less.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
General presentation. 24 March 2003 | | ‹#› Overall objective Main objective To develop and improve preventive and health-promoting efforts and the services.
Hans Wolf-Watz, professor, UCMR, MIMS, Department of Microbiology, Umeå University, Sweden, Antibiotic resistance a new.
Cross Border Animal Health Plan of Action – Kenya and Uganda Four Strategic areas 1. To improve prevention, management and control of cross border animal.
Key Strategies for Improving Use of Existing and New Antibiotics -the European Experience Otto Cars Professor Inf. Diseases, Uppsala University, Sweden.
THANK YOU!. Regional Adviser, Noncommunicable Diseases, WHO/EMRO Dr Ibtihal Fadhil.
Improving Antibiotic use through a Nationwide Decentralized Project – A Nine-Year Experience Cars O, Stålsby Lundborg C, Mölstad S Swedish Strategic Programme.
Sep-15 Provincial Collaboration: The BC Injury Prevention Leadership and Action Network (BCIPLAN) Dobmeier, Teresa 1, ▪ Herman, Matt 2 ; Scott, Vicky 2.
Briefing on 4th Meeting of Antimicrobial Resistance National Focal Points Ljubljana (Slovenia), 13 March 2008 Dominique L. Monnet Senior Expert, Antimicrobial.
Outcomes of the 16 th Regional Disaster Managers Meeting held from 9 th – 11 th August 2010 Presentation to the Pacific Humanitarian Team Monday 6 th December.
Roles of the DSCT team members Review of documents available.
Recommendation on prudent use of antimicrobial agents in human medicine – Slovenian experiences Intersectoral Coordination Mechanism Prof. Milan Čižman,
The e-Bug Project Implementation The Russell Hotel 3rd – 4th September 2009.
WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.
The Swedish Experience Otto Cars Prof. Infectious Diseases Uppsala University Hospital Sweden.
Communicating and disseminating EU research Charlotte Haentzel European Commission’s Representation in Sweden.
Telematikplattform für Medizinische Forschungsnetze (TMF) e.V. TMF – A Common Platform for Medical Research Networks in Germany Improving the Organisation.
European Union Network for Patient Safety and Quality of Care BMJ Forum. Paris. April 10, 2014 Good Organisational Practices for Exchange Mechanism Work.
Potential Roles for Health Technology Assessment Agencies: Opportunities and Challenges for an Effective Health Technology Assessment Practice at the Meso.
National antibiotic program in the Czech Republic NAP-CZ Vlastimil Jindrák and Subcommitte for antibiotic policy ČLS JEP.
European Commission Introduction to the Community Programme for Employment and Social Solidarity PROGRESS
The impact on practice, costs and outcomes of New Roles for health professionals in Europe (MUNROS) Antoinette de Bont/ associate professor/ Erasmus University.
Institut Català d’Oncologia ICO DiR. The ‘Qualy’ End of Life Care Observatory - WHO Collaborating Centre for Public Health Palliative Care Programmes Central.
South East Wales Critical Care Network Dr George Findlay, Lead Clinician Jennie Willmott, Network Manager.
A presentation of The Association of the Pharmaceutical Industry in Norway (LMI)
Swedres 2005 Swedres 2005 Figures and tables. Swedres 2005 Table Total use of antibacterial drugs for systemic use in Sveden , DDD/1000/day.
Towards a National Alliance against Chronic Respiratory Diseases Nikolai Khaltaev, MD, PhD March 2006, GARD General Meeting, Beijing, China.
Early School Leaving: A pathway for change Petra Goran DG Education and Culture.
E u r o p e a n C o m m i s s i o nCommunity Research Global Change and Ecosystems EU environmental research : Part B Policy objectives  Lisbon strategy.
European Antibiotic Awareness Day Sarah Earnshaw & Dominique L. Monnet.
Nurses´ role in tobacco control Mona Wahlgren, RN Chair, Swedish Nurses against Tobacco Tobacco Control Unit, Visby Hospital.
Perspectives on containing antimicrobial resistance – ways to go … Karl Ekdahl, Strategic Advisor on behalf of Zsuzsanna Jakab, Director European Centre.
Patients access to investigational drugs Steinar Aamdal Dept. of Clinical Cancer Research Oslo University Hospital.
Millennia 2015: Connecting for Health Dr Joan Dzenowagis Liège, Belgium 7-8 March 2008.
Bo Jordin Bo Jordin, MD Director of Primary Care Brugge Nov 28-29th mobile
1 Brussels 16 January What is HOPE? HOPE is an excellent example of the diversity of European healthcare system What is HOPE? HOPE is an excellent.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
NURSING INFORMATICS IN EUROPE By: MS. GLADYS D. PAPA, RN.
The network has established a forum for acute and community trusts as well as local authority commissioners to engage with, in order to increase public.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 28 – Consumer and Health Protection.
13 August 2012NUAS New forms of communicating research - in a European collaboration Ulla Bredberg, Science Communication Officer.
Towards a National eHealth Strategy Regional Symposium on E-government and IP Dubai - UAE November 2004.
WHO Regional Office for Europe
Research Challenges and Experiences
Networks of hospitals: building a common strategy for HAI prevention and control and antimicrobial policy Tomasz Ozorowski, M.D. University of Medical.
GLOBAL POINT PREVALENCE SURVEY
Antibiotics, prescribed for outpatients in Sweden (ATC group J01 Excluding methenamine), DDD/1000/day,
Improving Antibiotic use through a Nationwide Decentralized Project –
Towards Integrated Person Centered Health Service Delivery
Our vision Knowledge creates a sustainable world
Cancer Nurse Coordinator Resource: MCH Perspective
Sweden I 2006 National strategy
Presentation transcript:

STRAMA A 10 year perspective Swedish Strategic programme for the Rational use of Antimicrobial Agents and Surveillance of Resistance

How it all started Increasing incidence of Pc-resistant pneumococci (PRP) in Southern Sweden from ~2% to 8-15% in early 1990s Deterring international experiences Who is responsible for action? Discussion between competent authorities and professional organizations resulted in the formation of a national network for containment and professional organizations resulted in the formation of a national network for containment of antibiotic resistance (January 1995) of antibiotic resistance (January 1995) Increasing incidence of Pc-resistant pneumococci (PRP) in Southern Sweden from ~2% to 8-15% in early 1990s Deterring international experiences Who is responsible for action? Discussion between competent authorities and professional organizations resulted in the formation of a national network for containment and professional organizations resulted in the formation of a national network for containment of antibiotic resistance (January 1995) of antibiotic resistance (January 1995)

Coordination -nationally -locally Credibility -the messages need to be scientifically sound Communication -directed towards different target groups Collaboration -with other countries, EU and WHO

STRAMA - Primary objectives 1.Create a cross-sectorial national forum to - share information - formulate national strategies - support and initiate research activities - collaborate with media

Guidelines does not work unless they are implemented ! Implementation does not work unless there is local comittment and educational outreach !

STRAMA - Primary objectives 2. Stimulate the formation of regional/local STRAMA - groups in every county

STRAMA-groups were formed in every county. The County Medical Officers for Communicable have a leading role in these groups which include specialists from different medical fields The main objective is to evaluate the use antibiotics and antibacterial resistance in the region and to improve prescribing patterns

STRAMA Voluntary basis Supported by the Swedish Government with approx EUR yearly Support increased to EUR yearly

How did we use the financial Support from the Government? Tools for local implementation of guidelines Sales statistics, Resistance data National projects, new knowledge Newsletter, website Fund for local projects Educational activities “ STRAMA-days” Following the international scenario

Intensive care Hospital care Nursing homes Primary care Day care centres School children STRAMA projects initiated in many areas Barriers to implementation Clinical trials

MMM L K H F P O R E D T S W U AB C X Z Y AC BD I G N Number of antibiotic prescriptions per 1000 children 0-6 years MMM L K H F P O R E D T S W U AB C X Z Y AC BD I G N MMM L K H F P O R E D T S W U AB C X Z Y AC BD I G N MMM L K H F P O R E D T S W U AB C X Z Y AC BD I G N 1995

Sales of Antibiotics in the Nordic Countries DDD/1000 inhabitants/day

MRSA in Europe Data from EARSS.

Patient Prescriber Authorities MEDIA

STRAMA Success factors ? Culture and tradition Involving all stakeholders Voluntary No blame-game Bridging the gap between science and politics

EU and antibiotic growth promoters (AGPs) Sweden bans AGPs 1986 SE and FI when EU members, derrogations1995 Avoparcin – EU ban Dec 1996 Swedish Report 1997 AGP that are also used in medicine banned1999 SSC report 1999 No more AGPs in EU from 2006

Coordination -nationally -locally Credibility -the messages need to be scientifically sound Communication -directed towards different target groups Collaboration -with other countries, EU and WHO